Is the cell therapy sector outperforming the major indices?

By Dr. Matthew Watson

Tweet 

So here's what I did today.  I built a portfolio of public companies focused exclusively or predominately in the cell therapy space.  I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses.  The portfolio sits at 29 companies.  Here's the list:

Here's how the portfolio performs against the Dow Jones, Standard and Poor's, and NASDAQ indices so far this year.

When looking at the period 1 January 2012 to 10 August 2012, the cell therapy portfolio is up 42%, Dow Jones up 8%, Standard and Poor's up 12% and NASDAQ up 16%.

In the context of how much we hear about how harsh this sector is or has been on investors, I found today's analysis interesting and, honestly, pleasantly surprising.

This snapshot is useful but has its limitations. I'm relying on Google Finance for accuracy of the information provided.  Do your own due diligence. Invest accordingly.  I hope this helps.

--Lee

This snapshot has been brought to you by Cell Therapy Group: all cell therapy, all the time! 🙂

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Related Post

• Commercialization of Regenerative Medicine: Learning from Spin-Outs - April 28th, 2013
• 2013 Annual Regenerative Medicine Industry Report - April 21st, 2013
• Cell Therapy Blog welcomes 2013 - January 6th, 2013
• The Accuracy of Adipose Stem Cell Doses - December 23rd, 2012
• A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments - December 16th, 2012
• The ROI on pant-wearing and other social media tips - December 16th, 2012
• Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. - December 2nd, 2012
• Cell Therapy Industry Group Welcomes its 4,000th member - November 11th, 2012
• GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. - November 4th, 2012
• CIRM addresses some tough questions. Is it all just glass towers and basic research? - October 21st, 2012
• Cell therapy portfolio outperforms major indices year-to-date - October 14th, 2012
• The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. - September 30th, 2012
• Anticipated short-term cell therapy industry clinical milestones - September 30th, 2012
• Two lessons I learned this week. - September 16th, 2012
• Are some cell counts too good to be true? Why some companies' product data may mislead. - September 2nd, 2012
• FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) - July 29th, 2012
• Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing - June 17th, 2012
• Industry-sponsored cardiovascular cell therapies. Some metrics. - May 27th, 2012
• Cell-based Cancer Immunotherapies. Some metrics.. - May 20th, 2012
• Another > $100M month for companies in the cell therapy space - May 6th, 2012
• Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? - March 11th, 2012
• 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? - January 1st, 2012
• Inactive and recently failed or terminated phase III or II/III cell therapy trials - December 18th, 2011
• Recently approved cell therapy products - December 18th, 2011
• Active phase III or II/III cell therapy trials - December 11th, 2011
• Sabrina Cohen Foundation Thanks Stem Cell Researchers - November 27th, 2011
• Commercializing Cell-based Regenerative Medicines - November 13th, 2011
• Cell Therapy & Regenerative Medicine Domains Available - September 25th, 2011
• Commercial-stage Cell Therapy Companies and Products - September 18th, 2011
• Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy - September 18th, 2011
• Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. - August 14th, 2011
• Clinical trial costs - July 31st, 2011
• Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations - July 10th, 2011
• In vivo cell trafficking just took a leap forward - July 3rd, 2011
• Cell Therapies: Commercializing a New Class of Biopharmaceuticals - February 12th, 2011
• The LinkedIn Cell Therapy Industry Group - 1,000 members strong - January 15th, 2011
• Careers in cell therapy & regenerative medicine - October 11th, 2010
• FDA files injunction again Regenerative Sciences citing Regenexx violates regulations - August 12th, 2010
• The changing face of PR and why it matters to regenmed - June 12th, 2010
• Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 - May 22nd, 2010
• Google to Invest in Regenerative Medicine - May 5th, 2010
• Latest Cell Therapy Approval by FDA. Dendreon's Provenge. - April 30th, 2010
• Stem cells for a Webby! - April 28th, 2010

Regenerative Medicine Comments Off on Is the cell therapy sector outperforming the major indices? | August 12th, 2012

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,962)
• Cardiac Stem Cells (1,269)
• Global News Feed (3,335)
• Integrative Medicine (105)
• IPS Cell Therapy (468)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,198)
• Spinal Cord Stem Cells (950)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy